Guangzhou Double Bioproducts Co., Ltd   Report issue

For profit Phase 3
Founded: Guangzhou China (2001)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2013
NCT02630264
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (3)

cisplatin (platinol) (1 trial)

endostatin (endostar) (1 trial)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Squamous Cell (Phase 3)

Head and Neck Neoplasms (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3